Life Sciences Tools and Services
Company Overview of SomaLogic, Inc.
SomaLogic, Inc. operates as a life science tools and clinical diagnostics company. It offers Slow Off-rate Modified Aptamer (SOMAmer) technology to develop and commercialize proteomic life sciences research tools for the research community; and discover, develop, and commercialize life science research tools and breakthrough clinical diagnostic products that transform healthcare. The company also provides SOMAscan assay, a protein biomarker discovery tool for the life sciences community; SOMAmer reagents, which enable a host of life science applications, including quantitative measurement of individual proteins, histochemistry of frozen tissue samples, flow cytometry, and affinity purificati...
2945 Wilderness Place
Boulder, CO 80301
Founded in 1999
Key Executives for SomaLogic, Inc.
Chief Executive Officer and Director
Founder and Chairman of the Board
Chief Medical Officer Emertius
Compensation as of Fiscal Year 2015.
SomaLogic, Inc. Key Developments
SomaLogic, Inc. Announces Agreement to Place SOMAscan Proteomics Assay at Manitoba Centre for Proteomics and Systems Biology
Feb 4 15
SomaLogic, Inc. announced that the University of Manitoba's Centre for Proteomics and Systems Biology (MCPSB) is the first SOMAscan™ assay 'Early Access' site outside of the United States. It is expected that the assay will be installed and fully functional at the Centre by the middle of 2015, under the leadership of Director John A. Wilkins, Ph.D. SOMAmer® (Slow Off-rate Modified Aptamer) reagents, which are at the center of SomaLogic's proteomics platform, are a new class of superior protein-binding reagents that combine the best properties of both monoclonal antibodies and traditional aptamers. The SOMAscan assay, which incorporates 1,129 different SOMAmer reagents, can efficiently, accurately, and rapidly measures proteins across a wide range of concentrations in small volumes of multiple biological sample types. SomaLogic is continuing to expand access to its SOMAscan assay through its placement in leading academic research centers. Current sites, in addition to MCPSB, include Massachusetts General Hospital, the University of Pennsylvania, the US National Institutes of Health, and the University of Colorado Denver, with several more expected to be announced in the coming months.
SomaLogic, Inc. Announces Deployment of SOMAscan Proteomics Assay at University of Colorado Denver
Nov 18 14
SomaLogic, Inc. announced that the SOMAscan assay, a breakthrough proteomics platform, will be deployed at the University of Colorado Denver, Anschutz Medical Campus. The assay will be performed for UCD’s basic and clinical researchers under the direction of Mark Geraci, MD, Head of the Division of Pulmonary Sciences and Critical Care Medicine, and Bifeng Gao, PhD, Director and Manager of UCD’s Genomics and Microarray Core. It is expected that the SOMAscan assay will be installed and fully functional at UCD by early 2015.
SomaLogic, Inc. Announces Extension of Multi-Year Collaboration Agreement with Novartis Institutes for BioMedical Research
Oct 20 14
SomaLogic, Inc. announced that Novartis has extended its multi-year research agreement for the development and application of SomaLogic's unique proteomics technology to Novartis' drug discovery and development efforts. Novartis will also take an equity position in SomaLogic under the agreement extension. Under the previous collaboration agreement, scientists at the Novartis Institutes for BioMedical Research and SomaLogic worked together to build an enhanced proprietary version of SomaLogic's SOMAscan proteomics assay for NIBR. The collaboration also included development of specific novel SOMAmer binding reagents for multiple preclinical and clinical applications in NIBR's research and development portfolio. The collaboration extension announced will enhance and expand these efforts in addition to the equity investment in SomaLogic. Other specific terms of the agreement were not disclosed. Compared to other current proteomic technologies, SomaLogic's offerings provide researchers with unprecedented power for protein biomarker discovery, diagnostics development, and pharmaceutical discovery and development. SOMAmer reagents, which are at the center of SomaLogic's proteomics platform, are a new class of superior protein-binding reagents that combine the best properties of both monoclonal antibodies and traditional aptamers. They have wide applicability in many current preclinical and clinical analytical assays, including quantitative high-content screening, targeted panels, flow cytometry, histochemistry, functional assays, and biophysical methods. SomaLogic's commercially available SOMAscan assay, which incorporates 1,129 different SOMAmer reagents, can efficiently, accurately, and rapidly measure proteins across a wide range of concentrations in small volumes of multiple biological sample types.
Similar Private Companies By Industry
Recent Private Companies Transactions
October 17, 2014